Search

Displaying results 571 - 580 of 6198 in total
  1. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA. … Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4.

  2. Drug

    Levodopa

    go.drugbank.com/drugs/DB01235
    ApprovedInvestigational

    Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after … The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].

    Mixtures: Prolopa Cap 100-25, Prolopa Cap 200-50
  3. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.

  4. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide

  5. Drug

    Lormetazepam

    go.drugbank.com/drugs/DB13872
    Approved

    Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [L927]. … It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

  6. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions. … [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012.

  7. Drug

    Meticillin

    go.drugbank.com/drugs/DB01603
    ApprovedInvestigational

    One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.

  8. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation.

  9. Drug

    Capecitabine

    go.drugbank.com/drugs/DB01101
    ApprovedInvestigational

    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.

  10. Drug

    Potassium nitrate

    go.drugbank.com/drugs/DB11090
    ApprovedInvestigational

    It is administered orally doses up to 30 g per animal per day [L1736]. … Potassium nitrate is an inorganic salt with a chemical formula of KNO3.

    Mixtures: DOLNI - K GEL CON FLUOR, DOLNI-K GEL CON FLUORUROProducts: DOLNI - K ® ENJUAGUE BUCAL